I would now like to turn the call over to Liz Krutoholow, VP for Investor Relations. Please go ahead. Thank you. Good afternoon and welcome to Tempus' first quarter 2025 conference call.

I would now like to turn the call over to Liz Krutoholow, VP for Investor Relations. Please go ahead. Thank you. Good afternoon. And welcome to Tempus’ first quarter 2025 conference call.

(Operator Instructions) Thank you. I would now like to turn the call over to Liz Krutoholow, VP for Investor Relations. Please go ahead. Thank you. Good afternoon and welcome to Tempus' first quarter ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study ...

Tempus enters earnings with strong tailwinds but elevated scrutiny. The stock has surged over 80% in the past six months, and analysts have maintained tight but bullish targets — averaging $61. ...

The deals call for Pathos AI, another Chicago company co-founded by Lefkofsky, to build the oncology model using Tempus data, for which it will pay Tempus $200 million in data licensing and model ...

CHICAGO, May 05, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of ...

Tempus AI Inc. TEM during the first quarter secured a multi-million dollar deal to build “the world’s largest foundation model for oncology.” “And this is big for a few reasons,” said ...

Acquisition related expenses consist of legal, diligence, accounting, and financing costs incurred for the acquisitions of Ambry and Deep 6 during the three months ended March 31, 2025.

Tempus AI Inc. (TEM) reported its first-quarter 2025 earnings, showcasing a robust revenue increase of 75.4% year-over-year, reaching $255.7 million, surpassing the forecast of $248.5 million.

The Chicago-based startup formed in 2020 by Tempus AI executives Ryan Fukushima and Eric Lefkofsky is using an artificial intelligence platform, PathOS, to develop drugs, primarily in the oncology ...